About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 1511 record(s)
Req # A-2022-000950
Adverse Drug Reactions (ADRs). Report numbers: E2B_05027596, E2B_05027612, E2B_05033018, E2B_05032795, E2B_05032922, E2B_05032891, E2B_05020626, E2B_05027308, E2B_05027427.Organization: Health Canada
November 2022
Req # A-2022-000954
Adverse Drug Reaction (ADR) for VEKLURY. Report number: 001002947.Organization: Health Canada
November 2022
Req # A-2022-000973
Adverse Drug Reactions (ADRs). Report numbers: 001007504, 001007502, 001006591, 001006422, 001005764, 001005078, 001005759.Organization: Health Canada
November 2022
Req # A-2022-000980
Adverse Drug Reaction (ADR). Report number: 001005562.Organization: Health Canada
November 2022
Req # A-2022-001001
Adverse Drug Reaction (ADR). Report number: 001003685.Organization: Health Canada
November 2022
Req # A-2022-001021
Adverse Drug Reactions (ADRs). Report numbers: 001008150, 000999806, 000993061, 001006372.Organization: Health Canada
November 2022
Req # A-2022-001031
Adverse Drug Reaction (ADR) for Asaphen E.C. Report number: 000993038. Adverse Drug Reaction (ADR) for Asaphen E.C.: 000993038.Organization: Health Canada
November 2022
Req # A-2022-001118
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-115542-678.Organization: Health Canada
November 2022
Req # A-2016-000411
The reviewer’s comments and correspondence pertaining to the safety, efficacy, labelling and specifically the approval for Gynecare TVT abdominal Access system approved for use in Canada on January 4, 2002 on the transvaginal mesh products manufactured by Johnson & Johnson.Organization: Health Canada
November 2022
Req # A-2017-000117
All records relating to complaints received by Health Canada related to the product Dukoral.Organization: Health Canada
November 2022